NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228

Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228

1.1 Thalidomide in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate.

1.2 Bortezomib in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:

  • high-dose chemotherapy with stem cell transplantation is considered inappropriate and

  • the person is unable to tolerate or has contraindications to thalidomide.

https://www.nice.org.uk/guidance/TA228

 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.